SWMP
CRSP icon

Signature Wealth Management Partners’s CRISPR Therapeutics CRSP Stock Holding History

Signature Wealth Management Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Hold
4,250
– – 0.11% 109
2026
Q1 		$202K Hold
4,250
– – 0.1% 112
2025
Q4 		$223K Buy
+4,250
New +$255K 0.11% 110

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Signature Wealth Management Partners's CRSP Position: Q2 2026 in Review

Signature Wealth Management Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 4,250 shares worth $232K. The position accounts for 0.11% of the portfolio, ranked #109.

Signature Wealth Management Partners first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 299 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Signature Wealth Management Partners held 4,250 shares of CRISPR Therapeutics worth $232K as of Q2 2026.
  • Signature Wealth Management Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.11% of Signature Wealth Management Partners's portfolio in Q2 2026, its #109 holding.
  • Signature Wealth Management Partners first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 299 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Signature Wealth Management Partners's 13F filing for Q2 2026, filed 29 Jul 2026.